Global Pricing Innovations

This page shows the latest Global Pricing Innovations news and features for those working in and with pharma, biotech and healthcare.

Global Pricing Innovations and Partners4Access partner on market access

Will collaborate on orphan drug pricing and access solutions. Global Pricing Innovations and Partners4Access have formed a strategic partnership to offer pricing and access solutions for orphan drugs. ... Founder and chief executive of Global Pricing

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest appointments

GPI appoints commercial director

Alan Stewart joins the life science management consultancy's executive team. London, UK-based Global Pricing Innovations has strengthened its executive team with the appointment of Alan Stewart as commercial director. ... Stewart joins the pharmaceutical

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

Global Pricing Innovations Ltd (GPI)

Global Pricing Innovations supports price decision-making through data-driven insights and bespoke analytical solutions. ... Global Pricing Innovations Ltd (GPI).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Working together against COVID-19: Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19: Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?: Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....